The estimated Net Worth of Cameron Durrant is at least $3.96 Million dollars as of 2 March 2022. Dr Durrant owns over 40,000 units of Humanigen stock worth over $2,527 and over the last 16 years he sold HGEN stock worth over $1,680,942. In addition, he makes $2,275,314 as Chairman & CEO at Humanigen.
Dr has made over 2 trades of the Humanigen stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 40,000 units of HGEN stock worth $93,600 on 2 March 2022.
The largest trade he's ever made was selling 81,441 units of Humanigen stock on 14 June 2021 worth over $1,680,942. On average, Dr trades about 7,144 units every 15 days since 2008. As of 2 March 2022 he still owns at least 70,000 units of Humanigen stock.
You can see the complete history of Dr Durrant stock trades at the bottom of the page.
Dr. Cameron Durrant M.B.A., M.D., MBA is the Chairman & CEO at Humanigen.
As the Chairman & CEO of Humanigen, the total compensation of Dr MBA at Humanigen is $2,275,314. There are no executives at Humanigen getting paid more.
Dr MBA is 61, he's been the Chairman & CEO of Humanigen since . There are no older and 6 younger executives at Humanigen.
Cameron's mailing address filed with the SEC is 1000 Marina Blvd, Brisbane, CA 94005, USA.
Over the last 5 years, insiders at Humanigen have traded over $2,588,252,690 worth of Humanigen stock and bought 2,107,496 units worth $5,417,461 . The most active insiders traders include Dale Cheval Holdings, Ltd.B..., Dale Black Horse Capital Ma..., and Bay Ltd. Nomis. On average, Humanigen executives and independent directors trade stock every 34 days with the average trade being worth of $7,693. The most recent stock trade was executed by Dale Black Horse Capital Lp... on 18 October 2023, trading 386,350 units of HGEN stock currently worth $3,864.
Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of anti-inflammatory immunology and immuno-oncology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which has completed Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that is in Phase II clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which has completed pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
Humanigen executives and other stock owners filed with the SEC include: